Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Cureus ; 14(12): e32905, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36699772

RESUMO

Tuberculosis (TB) is a contagious disease caused by the bacilli Mycobacterium tuberculosis complex. Currently, about a quarter of the world's population is infected with Mycobacterium tuberculosis. According to the World Health Organization, in 2018, Portugal had a TB incidence rate of about 24 cases per 100,000 inhabitants. It is estimated that 5-15% of individuals with latent TB infection progress to active TB. Isoniazid is one of the most widely used drugs for the treatment of active and latent TB. However, care must be taken with the possible development of toxicity, particularly hepatic. The authors report a case of a 60-year-old woman diagnosed with latent TB who started therapy with isoniazid. Five months later, she developed acute liver failure secondary to the drug, requiring liver transplantation, with a favorable clinical outcome. Thus, we intend to alert to the potential toxicities of isoniazid, establishing follow-up strategies in patients on this therapy.

2.
Arch Pharm (Weinheim) ; 347(6): 381-6, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24664885

RESUMO

New quaternary ammonium salt-type compounds with lipophilic cholesterol and terpene moieties were synthesized. The compounds showed promising antibacterial and antimycobacterial activities. Those compounds containing the cholesterol moiety showed significant activity against Staphylococcus aureus, Staphylococcus epidermidis, and Enterococcus faecium. On the contrary, the antimycobacterial activity increased with the presence of the terpene unit in the molecule.


Assuntos
Anti-Infecciosos/síntese química , Anti-Infecciosos/farmacologia , Colesterol/síntese química , Colesterol/farmacologia , Compostos de Amônio Quaternário/síntese química , Compostos de Amônio Quaternário/farmacologia , Terpenos/farmacologia , Colesterol/análogos & derivados , Desenho de Fármacos , Enterococcus faecium/efeitos dos fármacos , Enterococcus faecium/crescimento & desenvolvimento , Fungos/efeitos dos fármacos , Fungos/crescimento & desenvolvimento , Testes de Sensibilidade Microbiana , Estrutura Molecular , Mycobacterium/efeitos dos fármacos , Mycobacterium/crescimento & desenvolvimento , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/crescimento & desenvolvimento , Staphylococcus epidermidis/efeitos dos fármacos , Staphylococcus epidermidis/crescimento & desenvolvimento , Relação Estrutura-Atividade
3.
Chinese Pharmaceutical Journal ; (24): 101-103, 2012.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-860841

RESUMO

OBJECTIVE: To identify a characteristic chemical marker of Ranunculi Ternati Radix and establish a HPLC method for determination of its content. METHODS: Various chromatographic methods were applied to isolate the marker 4-[formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl] butanoic acid, and its structure was elucidated by spectroscopic methods. The HPLC was performed on Agilent TC-C18 column (4.6 mm × 250 mm, 5 μm) using CH3OH-H2O (containing 0.4% acetic acid) as the mobile phase. The flow rate was 1.0 mL · min-1 and the detection wavelength was set at 292 nm. RESULTS: 4-[formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl] butanoic acid was isolated and identified as the chemical marker. The HPLC method showed good linearity within the range of 0.372-1.302 μg (r2=0.9998). The average recovery of 4-[formyl-5-(hydroxymethyl)-1H-pyrrol-1-yl] butanoic acid was 100.89% (n=6, RSD=0.83%). CONCLUSION: This method is simple, rapid and reliable for the quality control of Ranunculi Ternati Radix. Copyright 2012 by the Chinese Pharmaceutical Association.

4.
Braz. j. pharm. sci ; 45(2): 331-337, Apr.-June 2009. graf, tab, ilus
Artigo em Inglês | LILACS | ID: lil-525912

RESUMO

Tuberculosis remains a major public health problem, especially in developing countries. Brazil presents the largest number of cases in Latin America and is among the 22 countries considered priorities by the World Health Organization (WHO). The Rio de Janeiro state has the largest number of cases registered in the country. The treatment of patients, commonly, makes use of the drugs isoniazid and rifampicin for six months. This study aimed to develop and validate an electroanalytical methodology, using the technique of differential pulse voltammetry for the determination of these drugs in the associated form, in order to evaluate the quality of medicines distributed in the state of Rio de Janeiro. The potential reduction for the isoniazid and rifampicin were -1.10 and -0.90 V. The developed and validated electroanalytical method presented a linear range of 0.25 to 1.25 mg/L to isoniazid, limits of detection and quantification of 0.05 and 0.14 mg/L, and recovery of 98.2 ± 0.4 percent; a tracking linear of 0.40 to 2.00 mg/L for rifampicin, with limits of detection and quantification of 0.07 and 0.19 mg/L and recovery of 95.8 ± 0.6 percent. Six lots of medicines from two pharmaceutical companies were analyzed. Only one of the samples showed unsatisfactory levels of rifampicin.


A tuberculose continua sendo um importante problema de saúde pública, especialmente em países em desenvolvimento. O Brasil apresenta o maior número de casos da América Latina, estando entre os 22 países considerados prioritários nas ações de controle da doença pela Organização Mundial da Saúde (OMS). No Brasil, o Rio de Janeiro é o estado com o maior número de casos registrados no país. O tratamento de doentes com tuberculose faz uso dos fármacos isoniazida e rifampicina durante seis meses. O presente trabalho objetivou desenvolver e validar metodologia eletroanalítica, utilizando a técnica de voltametria de pulso diferencial, para a determinação desses dois princípios ativos na forma associada e avaliar a qualidade dos medicamentos distribuídos no estado do Rio de Janeiro. Os potenciais de redução para a isoniazida e rifampicina foram respectivamente -1,10 e -0,90 V. O método eletroanalítico desenvolvido e validado apresentou para a isoniazida faixa linear de 0,25 a 1,25 mg/L, limites de detecção e quantificação de 0,05 e 0,14 mg/L e recuperação de 98,2 ± 0,4 por cento; para a rifampicina faixa linear de 0,40 a 2,00 mg/L, limites de detecção e quantificação de 0,07 e 0,19 mg/L e recuperação de 95,8 ± 0,6 por cento. Foram analisados 6 lotes de medicamentos de dois laboratórios farmacêuticos. Apenas uma das amostras apresentou teor de rifampicina insatisfatório.


Assuntos
Composição de Medicamentos , Desenvolvimento Tecnológico/métodos , Infecções por Mycobacterium não Tuberculosas , Isoniazida/análise , Rifampina/análise , Técnicas de Patch-Clamp/métodos , Tuberculose Pulmonar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...